The creation of a clear approval pathway for biosimilar drugs remains a daunting task for the Food and Drug Administration, despite the fact that it's prescribed by law through the Patient Protection and Affordable Care Act. But when those lower-priced, generic versions of some staggeringly expensive bioengineered medicines do finally come to market, they're likely to have a profound effect on the nation's outlays for specialty pharmaceuticals.
The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.
Sundial Brands, the maker of natural skin and hair brand SheaMoisture, has expanded its SheaMoisture Baby Care Collection to more than 5,000 CVS/pharmacy stores, 1,500 Kroger locations and more than 700 Stop & Shop/Giant retail outlets nationwide, the manufacturer announced on Thursday.
The Consumer Healthcare Products Association on Wednesday applauded the Pennsylvania legislature and Gov. Tom Corbett for passage of House Bill 602, legislation requiring real-time, stop-sale technology to enable retailers to block illegal pseudoephedrine purchases at the point of sale.
The National Community Pharmacists Association praised Hawaii elected officials for enacting two new laws that, respectively, will give the state’s residents greater choice of where to fill their prescriptions and additional medical privacy protections.
Pharmacy ownership was once again a key aspect of McKesson ideaShare, as McKesson hosted its sixth annual RxOwnership program on June 29 to help advise independent pharmacy operators that are looking to buy or sell an existing store.
Many patients are not complying with their prescription drug therapies due to adverse side effects, even though some OTC drugs can treat them, according to a new study commissioned by a maker of products for dry mouth, one of the most common medication side effects.
A nonprofit pharmacy advocacy group has launched a new project that it said was aimed at ensuring fair audit standards for prescription drug claims paid under the Medicare Part D program and protecting pharmacies and patients from what it called unfair audit and conduct practices by pharmacy benefit managers.
The Food and Drug Administration has made a significant dent in its large backlog of generic drug applications thanks to amendments to last year's reauthorization of the Prescription Drug User Fee Act, the agency said.
With some studies showing that patients' failure to take their medications as directed costs the economy nearly $300 billion per year, one group is looking to tackle what it sees as part of the problem: doctors' and pharmacists' instructions to patients on how much medicine to take and when.
Amid mounting evidence of the negative clinical and economic consequences of medication nonadherence, research featured on the cover of this month’s Health Affairs breaks new ground by urging innovative approaches to improve medication adherence and to “achieve a higher-performing health system.”
Oregon Gov. John Kitzhaber, a Democrat, has signed what the National Association of Community Pharmacy has characterized as groundbreaking reform legislation that applies reasonable standards to how pharmacy benefit managers audit community pharmacies, provides increased transparency into generic prescription drug reimbursement and ensures that PBM administrators of prescription drug claims are registered within the state.